Trials / Completed
CompletedNCT05913115
A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer
A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main objectives of this study are: * To determine the recommended dose (RD) of FPA144 in participants with gastric or gastroesophageal cancer (hereafter referred to as gastric cancer) * To evaluate the safety of escalating doses of FPA144 in participants with gastric cancer * To characterize the pharmacokinetic (PK) profile of single and multiple doses of intravenously administered FPA144 in participants with gastric cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FPA144 | FPA144 will be administered intravenously Q2W. |
Timeline
- Start date
- 2017-06-12
- Primary completion
- 2018-06-19
- Completion
- 2018-06-19
- First posted
- 2023-06-22
- Last updated
- 2023-06-22
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT05913115. Inclusion in this directory is not an endorsement.